163 articles - From Friday Aug 15 2025 to Friday Aug 22 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Gastroenterology |
|---|
AGA Clinical Practice Update on Management of Hepatitis Delta: Commentary. The purpose of this American Gastroenterological Association (AGA) Clinical Practice Update is to facilitate understanding and improve clinical management of patients with hepatitis delta virus infection. This commentary was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Gastroenterology. |
| Gastrointest Endosc |
meta-analyses and systematic reviews
| Aliment Pharmacol Ther |
|---|
Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic Studies. Heterogeneity and potential for bias indicates that findings should be interpreted with caution. Standardised protocols to ensure robust methodology and allow pooling of large-scale data are required before these findings can be used in clinical practice (PROSPERO CRD42023431977). |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment. Through 5 years, rates of virologic suppression were high in East Asian patients treated with TAF or switched from TDF to TAF. TAF and TDF were well tolerated, with improved renal and bone safety observed in patients switching from TDF to TAF. |
| Am J Gastroenterol |
Avoidant/restrictive eating in people with and without bowel symptoms in the general population: Prevalence, Clinical Profile and Associated Factors. Avoidant/restrictive eating is common in individuals with bowel symptoms and associated with a more severe clinical profile, indicating a need to discuss eating behavior with patients. However, avoidant/restrictive eating is also common in individuals in the general population without bowel symptoms. |
Can symptoms and medical history predict outcomes for hydrogen and methane breath testing? This large questionnaire study demonstrated that IBS-like symptoms, refractory gastroesophageal reflux symptoms, and skin conditions are associated with outcomes on HMBT. These findings support the use of HMBT in accordance with current clinical guidelines. |
Increased mortality associated with sarcopenia in inflammatory bowel disease: a long-term prospective cohort study. Probable and confirmed sarcopenia increase the risk of long-term mortality in IBD patients. Sarcopenia assessment can help risk stratification for prognosis in older IBD patients. |
Safety of Esophageal Dilation Procedures in Patients on Antithrombotic Therapy: A US Collaborative Network Cohort Study. DAPT was numerically associated with a higher risk of bleeding, but this did not reach statistical significance. These findings aim to inform the clinical decision-making in pre- and post-procedure management of esophageal dilation procedures. |
The impact of integrating pelvic MRI at diagnosis on early detection of perianal Crohn's disease in pediatrics. These patients needed more and earlier perianal surgery and had higher biologic use despite their perianal disease being subclinical. Adding routine MR imaging at time of pediatric CD diagnosis may help inform treatment decisions and improve these outcomes. |
| Clin Gastroenterol Hepatol |
Artificial Intelligence for Quantifying Endoscopic Mucosal Ulceration in Crohn's Disease. Performance of CVE for CD was similar in the SEAVUE validation cohort. CVE provides a means for automated ulceration and mucosal injury quantitation that shows conceptual agreement with SES-CD and offers new capabilities to improve the granularity and personalization of endoscopic disease assessment in CD. |
Effect of five dietary emulsifiers on inflammation, permeability, and the gut microbiome: a placebo-controlled randomized trial. In this double-blind placebo-controlled exploratory trial, emulsifier supplementation lowered SCFA concentration compared to placebo. Emulsifier supplementation did not impact intestinal or systemic inflammation, or metabolic endpoints. Cholesterol levels decreased after two weeks of EFD. These results point towards potential intestinal benefits of limiting dietary emulsifiers in the diet, requiring further investigation. |
Real-World Experience of Upadacitinib Reinduction and High Dose Maintenance Therapy in Inflammatory Bowel Disease. Most patients with IBD who lose response to UPA when dose reduced in maintenance can be recaptured with 45mg QD. Among these, continuing 45mg QD for maintenance is effective, and appears safe. |
Real-time use of computer-aided diagnosis in the optical diagnosis of gastric neoplasia: A multicenter randomized controlled trial. The present CADx assistance did not improve the non-expert optical diagnosis of gastric neoplasia. Further improvements of the CADx with WLI are needed by changing the confidence level cut-off and additional training on easily missed neoplasias. Another option is CADx with magnifying narrow band imaging. (Japan Registry of Clinical Trials, number jRCTs032210171). |
Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study. Tofacitinib and ustekinumab are similarly effective to induce and maintain CFREM after anti-TNF failure in UC. However, tofacitinib could be favored in case of multiple therapeutic failures (≥ 3 biologics) and primary failure to any biologic. |
Whole-Exome Sequencing-Identified Germline Variants Underlie High Familial Risk and Early-Onset Colorectal Cancer in Taiwan. These findings improve our understanding of germline genetics in Taiwanese CRC, support better screening and management strategies, and highlight the need to expand Asian variant databases for improved risk assessment and care. |
| Endoscopy |
Efficacy of artificial intelligence for adenoma detection in water exchange colonoscopy: A two-center randomized controlled trial. For WE colonoscopy, integrating CADe statistically increased APC without prolonging the withdrawal time or causing a concomitant increase in non-neoplastic lesion resection. |
Endoscopic management of refractory gastrointestinal-tracheobronchial fistulas with two novel occluders: a comparative cohort study. All procedure-related AEs were mild, occurring in five DU (13.9%) and three MU patients (6.0%). The MU occluder showed greater potential for sustained occlusion than the DU occluder and may be a viable option for refractory GI-tracheobronchial fistulas, although further prospective studies are needed. |
National root-cause analysis of 1724 post-colonoscopy colorectal cancers demonstrates avoidable harm. This is the largest detailed PCCRC review to date. The majority of PCCRCs were avoidable and caused significant harm. This study clarifies the causes of diagnostic delays and highlights high-risk areas of the colon and high-risk patients, and what needs to be done to reduce PCCRC in the future. |
Reducing the environmental impact of gastrointestinal endoscopy: a prospective study on waste management through waste segregation and staff education. Targeted interventions such as staff education and structured waste segregation protocols substantially reduced RMW and associated GHG emissions in a high-volume endoscopy unit. These results suggest that simple, low-cost changes may improve environmental sustainability in clinical practice. |
STAndardization of Reports (the STAR project) Upper gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. A suggestion for a normal findings report is provided. Standardized reporting could enhance the quality of UGI endoscopy. |
Training esophagogastroduodenoscopy skills: a randomized multicenter trial comparing simulation-based training versus clinical training. SBT prior to CBT reduces the number of supervised procedures required to achieve independent procedural completion without negatively affecting patient satisfaction or increasing training costs. These findings support the routine implementation of SBT when learning EGD. |
| Gastroenterology |
Histologic response is associated with improved esophageal distensibility and symptom burden in pediatric eosinophilic esophagitis. Histologic remission is associated with improved esophageal distensibility over time in pediatric EoE patients. Baseline esophageal distensibility provides a quantitative marker of tissue remodeling and may help predict disease severity and fibrostenotic progression. |
| Gastrointest Endosc |
Clinical impact of combination of lesion-border findings and pit patterns for identifying invasive versus non-invasive neoplastic lesions in ulcerative colitis. One hundred and eighteen lesions were classified with distinct borders and 40 with indistinct borders. The diagnostic sensitivity, specificity, and accuracy of type II/III pit patterns were intramucosal, suggesting lesions suitable for endoscopic resection. |
Clinical utility of suprapapillary plastic stents for lifelong biliary drainage in unresectable malignant hilar biliary obstruction. SPPS, as the first stent for unresectable MHBO, was considered superior to SEMS for the intermittent maintenance of LBD. Achieving LBD success or extending TLBDF may help preserve therapeutic options. |
Comparison of endoscopic band ligation versus over-the-scope clip for colonic diverticular bleeding: A propensity score-matched cohort analysis. No significant differences in initial hemostasis, requirements for IVR or surgery, requirements of red blood cell transfusion, and adverse events were observed between the two groups. OTSC was more effective than EBL for reducing early recurrent bleeding rate in endoscopic hemostasis for CDB. |
Focused communication Three-dimensional volume estimates of pancreatic fluid collections in relation to clinical outcomes of endoscopic ultrasound-guided treatment. The maximum diameter represented a comparable model goodness-of-fit. PFC volume was associated with the outcomes of EUS-guided interventions, and the maximum diameter may be a reasonable surrogate. |
Optimal Interval of Screening Endoscopy for Reducing Gastric Cancer Mortality: A Nationwide Cohort Study. Patients who underwent screening at intervals ≤3 years had a significantly reduced risk of GC-specific mortality compared to those screened at intervals >3 years. A 3-year screening interval may be an effective strategy for high-risk regions. |
Performance comparison of quantitative and qualitative fecal immunochemical tests in community-based colorectal cancer screening. QnFIT exhibited lower positivity, higher DR at colonoscopy and PPV for CRC over qlFIT. Almost half of colonoscopy resources were saved by qnFIT, although adenoma and polyp were missed in population screening. |
| Gut |
Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial. As monotherapy for patients with HBV-HCC, SCG101 demonstrated pronounced antiviral and antitumour activities and a safety profile manageable with supportive care. SCG101's T-cell expansion, serum HBsAg drop and tumour response collectively underscore on-target activity. |
Global prevalence and gastrointestinal symptom burden of individuals with a history of cholecystectomy. Cholecystectomy is prevalent worldwide and varies across world regions. A history of this procedure is associated with a higher GI symptom burden, either due to new cholecystectomy-related symptomatic conditions, or persistent DGBI misattributed to biliary disease for which a cholecystectomy was erroneously performed. |
ISG15 deficiency in hepatic stellate cells promotes TGFβ2-induced liver fibrosis by counteracting CREB1 ISGylation. ISG15 regulated HSC activation and liver fibrosis in part via the CREB1/TGFβ2/SMAD2 regulatory pathway. Utilisation of ISG15-CREB1 signalling may be a potential therapeutic target for liver fibrosis. |
Intrahepatic donor microbiota-based metataxonomic signature detected in organ preservation solution enables prediction of short-term liver transplant outcomes. Donor intrahepatic microbial DNA signature predicts LT outcomes via immune-metabolic modulation. While causality requires further study, these findings position the graft microbiome as a novel biomarker and potential therapeutic target, paving the way for microbiome-informed precision care in transplantation. |
Mucosal transcriptomic landscape along the small and large intestines in individuals with and without type 2 diabetes. Our study offers a detailed mapping of the transcriptomic landscape in the human intestinal tract, demonstrating regionalised gene expression profiles tied to critical biological processes. Notable alterations in immune system activity in the large intestine were observed in individuals with T2D. The publicly available database generated from this study ( provides a valuable resource for exploring the mucosal transcriptome along the human intestinal tract. |
| Hepatology |
A novel mechanism involving USP53-regulated BSEP trafficking underlies low-GGT intrahepatic cholestasis. Loss of USP53 interaction with MYO5B and its p.(Arg824Cys) variant impaired BSEP trafficking in USP53- and MYO5B-asociated low-GGT intrahepatic cholestasis. These results provide a novel mechanism that underlies USP53-PFIC and implicates USP53 in the pathogenesis of MYO5B-PFIC. |
CX3CR1+ macrophages interact with HSCs to promote HCC through CD8+ T-cell suppression. Moreover, genetic deficiency of CX3CR1 in myeloid cells or pharmacological inhibition of retinol metabolism remarkably attenuated HCC development. We showed that CX3CR1+Ly6C+ macrophages migrate and interact with aHSCs in the peritumoral region where retinoids induce arginase-1 expression in CX3CR1+Ly6C+ macrophages, subsequently depriving CD8+ T cells of arginine and promoting HCC. |
Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution. TAMs, especially C5aR+ TAMs, were enriched in PVTT. C5aR+ TAMs contribute to the development of PVTT and poor prognosis by reshaping the immunosuppressive environment. |
Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma. Additionally, MMP9+ tumor-associated macrophages were enriched across IM and MO, which formed cellular niches with regulatory T cells and proliferative/exhausted T cells. Our findings deeply decipher the heterogeneous TMEs between IM and MO, which provide a comprehensive landscape of multifocal HCC. |
Human-induced pluripotent stem cell-based hepatic modeling of lipid metabolism-associated TM6SF2-E167K variant. Our findings indicate that induced hepatocytes generated from human-induced pluripotent stem cells carrying the TM6SF2-E167K recapitulate the effects observed in human hepatocytes from individuals with the TM6SF2 mutation. This study characterizes an in vitro model that can be used as a platform to identify potential clinical targets and highlights the therapeutic potential of targeting protein misfolding to alleviate ER stress and mitigate the detrimental effects of the TM6SF2-E167K mutation on hepatic lipid metabolism. |
Plasma FSTL-1 as a noninvasive diagnostic biomarker for patients with advanced liver fibrosis. A cutoff value ≤ 0.43 ng/mL was the optimal rule-out threshold, with a sensitivity of 84.62% (95% CI, 76.46%-90.30%) and a specificity of 79.51% (95% CI, 74.81%-83.53%), while ≥0.50 ng/mL was the best rule-in threshold, with a specificity of 86.41% (95% CI, 81.06%-90.43%) and a sensitivity of 70.67% (95% CI, 64.41%-76.23%). Plasma FSTL-1 has high diagnostic accuracy and could potentially reduce the need for liver biopsy in identifying patients with advanced liver fibrosis. |
Use of liver stiffness measurement for hepatocellular carcinoma risk stratification in metabolic dysfunction associated steatotic liver disease. LSM is associated with HCC risk in MASLD. HCC surveillance should be considered in non-cirrhotic MASLD with diabetes and LSM of ≥10 kPa. |
Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel. The panel acknowledged performance metrics of emerging methods may differ from other cancer screening programs given differences in populations, including higher risk of cancer development and competing risk of morality, and differences in diagnostic workflow in patients at risk of HCC. These data provide insights into the perceived value of HCC surveillance in an era of emerging blood- and imaging-based surveillance strategies. |
| J Hepatol |
Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels. Our findings demonstrate that the LONP1-DHODH interaction regulates orotic acid metabolism and alleviates MASH-induced liver fibrosis. Impact and implications Liver fibrosis is one of the main histological determinants of MASH, a disease that parallels the worldwide surge in metabolic syndromes. This study reveals that LONP1 links proteolytic surveillance to mitochondrial metabolic rewiring and regulates orotic acid metabolism, contributing to the progression of MASH-induced liver fibrosis. These findings suggest that targeting orotic acid or hepatocyte LONP1 may represent a promising therapeutic strategy. Further investigation into mitochondrial orotic acid metabolism may yield novel insights into the pathogenesis of liver fibrosis. |
Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acutely decompensated cirrhosis. RIPK3-associated cell death is an important driver of organ failure and mortality in AD/ACLF. Integrating plasma RIPK3 into prognostic models would enhance risk stratification and may guide personalised cell death inhibitor therapy in AD/ACLF patients. Impact and implications Our study underscores the pivotal role of Receptor-Interacting Protein Kinase 3 (RIPK3) as a biomarker in acute decompensation (AD) and acute-on-chronic liver failure (ACLF), linking its elevated levels with disease progression, organ dysfunction, and mortality. In liver biopsies, hepatic RIPK1 expression was significantly higher in ACLF than AD and correlated with disease severity and non-survival, supporting their hepatic origin. Through the integration of RIPK3 into predictive models, we provide a path towards personalized therapeutic strategies for AD by targeting necroptosis. This approach has the potential to revolutionize risk stratification, enhance clinical decision-making, and improve outcomes for these high-risk patients. |
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma. Lymphodepletion chemotherapy followed by ADP-A2AFP TCR T-cell therapy showed a manageable safety profile and preliminary indications of antitumor activity in these previously treated patients. Impact & implications Adoptive T-cell therapy could be a much-needed additional treatment strategy for advanced hepatocellular carcinoma. Clinicians and researchers interested in the development of adoptive T-cell therapies for advanced solid tumors will be interested to learn that in this phase I trial, ADP-A2AFP T-cell receptor T-cell therapy was associated with an acceptable benefit-to-risk profile and encouraging antitumor activity, illustrating the treatment potential of adoptive T-cell therapy for advanced hepatocellular carcinoma. Clinicaltrials Gov number NCT03132792; first posted 2017-04-08. |
Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma. Here we identified several prognostic and predictive biomarkers that may be useful for guiding adjuvant chemotherapy selection in resected EH-CCA. Further validation is required. Clinicaltrials Gov identifier NCT03079427 IMPACT AND IMPLICATIONS Here we performed comprehensive proteogenomic analyses within a prospective randomized trial of patients with extrahepatic cholangiocarcinoma (EH-CCA). The findings highlighted specific genomic and proteomic alterations that were associated with differential benefit from adjuvant chemotherapy regimens. The integration of multiomics data into a machine learning model provides a practical framework for stratifying patients and guiding treatment decisions, which may inform future clinical trials and biomarker-driven therapeutic strategies. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
Review Article: Impact of Alcohol Consumption on the Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease. Alcohol amplifies MASLD progression through synergistic mechanisms. Standardised evaluation of alcohol use is critical for risk stratification and the development of personalised treatment strategies. |
| Clin Gastroenterol Hepatol |
| Gastrointest Endosc |
| Hepatology |
| J Hepatol |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Clin Gastroenterol Hepatol |
| Endoscopy |
| Gastrointest Endosc |
| Gut |
| Hepatology |
| J Hepatol |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Clin Gastroenterol Hepatol |
| Gastroenterology |
| Gastrointest Endosc |
| Gut |